UK markets closed

NIKKEI 225
38,385.73
+29.67(+0.08%)
HANG SENG
19,073.71
-41.35(-0.22%)
CRUDE OIL
78.76
+0.74(+0.95%)
GOLD FUTURES
2,392.00
+32.10(+1.36%)
DOW
39,832.75
+274.64(+0.69%)
Bitcoin GBP
51,531.39
+3,118.49(+6.44%)

How to claim expenses at work without breaking the rules

Knowing more about tax rules can save you money

Marinus Pharmaceuticals, Inc. (MRNS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

1.3650

+0.0250

(+1.87%)

As of 02:23PM EDT. Market open.

Loading interactive chart…

Simply Wall St.
Earnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00
Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS ) just released its latest first-quarter report and things are not looking...
Zacks
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 0% and 10.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
RADNOR, Pa., May 08, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2024.